MedTrace Logo

Study in Patients With SCLC of Veliparib in Combination With Topotecan

NCT03227016 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-01-27

No results posted yet for this study

Summary

Phase I/II Study in Patients With Small Cell Lung Cancer (SCLC) of Veliparib in Combination With Topotecan

Conditions

  • Small Cell Lung Cancer SCLC

Interventions

DRUG

veliparib

Topotecan at increasing doses (1x or 2x per day) will be administered in each cycle.

DRUG

Topotecan

Topotecan at dose 1.25 mg/m2 will be administered in each cycle.

Sponsors & Collaborators

  • Central European Society for Anticancer Drug Research

    lead OTHER

Principal Investigators

  • Joachim von Pawel, MD · Askelios Klinik München Gauting

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2021-05-31
Completion
2021-06-30

Countries

  • Germany

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03227016 on ClinicalTrials.gov